Design, synthesis and biological evaluation of novel podophyllotoxin derivatives as tubulin-targeting anticancer agents

Authors:

Abstract
ContextPodophyllotoxin (PPT) derivatives, used in cancer therapy, require development toward enhanced efficacy and reduced toxicity.ObjectiveThis study synthesizes PPT derivatives to assess their anticancer activities.Materials and methodsCompounds E1-E16 antiproliferative activity was tested against four human cancer cell lines (H446, MCF-7, HeLa, A549) and two normal cell lines (L02, BEAS-2B) using the CCK-8 assay. The effects of compound E5 on A549 cell growth were evaluated through molecular docking, in vitro assays (flow cytometry, wound healing, Transwell, colony formation, Western blot), and in vivo tests in female BALB/c nude mice treated with E5 (2 and 4 mg/kg). E5 (4 mg/kg) significantly reduced xenograft tumor growth compared to the DMSO control group.ResultsAmong the 16 PPT derivatives tested for cytotoxicity, E5 exhibited potent effects against A549 cells (IC50: 0.35 +/- 0.13 mu M) and exceeded the reference drugs PPT and etoposide to inhibit the growth of xenograft tumours. E5-induced cell cycle arrest in the S and G2/M phases accelerated tubulin depolymerization and triggered apoptosis and mitochondrial depolarization while regulating the expression of apoptosis-related proteins and effectively inhibited cell migration and invasion, suggesting a potential to limit metastasis. Molecular docking showed binding of E5 to tubulin at the colchicine site and to Akt, with a consequent down-regulation of PI3K/Akt pathway proteins.Discussion and conclusionsThis research lays the groundwork for advancing cancer treatment through developing and using PPT derivatives. The encouraging results associated with E5 call for extended research and clinical validation, leading to novel and more effective cancer therapies.
Funding Information
  • Program for Taishan Scholar Project of Shandong Province (tsqn201812159)
  • Natural Science Foundation of Shandong Province (ZR2020MH375)
  • Scientific Research Foundation of Shandong Medical Association (YXH2021ZX001)
  • Traditional Chinese Medicine Science and Technology Development Plan of Shandong Province (2019-0747)
  • Projects of Medical and Health Technology Development Program in Shandong Province (202113050502)
  • Key R&D Program of Jining (2022YXNS148, 2022YXNS118, 2023YXNS037)
  • Doctoral Fund of Jining NO.1 People′s Hospital (2021-BS-008)

This publication has 26 references indexed in Scilit: